Llovet J M, Burroughs A, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2003, 362(9399): 1907-1917. [2]Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009[J]. CA Cancer J Clin, 2009, 59(4): 225-249. [3]Haraguchi N, Ishii H, Mimori K, et al. CD13 is a therapeutic target in human liver cancer stem cells[J]. J Clin Invest, 2010, 120(9): 3326-3339. [4]Chen Y, Yu D, Zhang H, et al. CD133+EpCAM+ phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 cells[J]. Int J Biol Sci, 2012, 8(7): 992-1004. [5]Zhang X W, Yan X J, Zhou Z R, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML[J]. Science, 2010, 328(5975): 240-243. [6]屈凤莲, 郝学志, 秦叔逵, 等. 亚砷酸注射液治疗原发性肝癌的Ⅱ期多中心临床研究[J]. 中华肿瘤杂志, 2011, 33(9): 697-701. [7]金世龙, 黄中荣, 陈华, 等. HuH7细胞系CD13+CD133+HCC细胞分选及CSCs特性分析[J]. 第三军医大学学报, 2012, 34(16): 1658-1662. [8]Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells[J]. Nature, 2008, 453(7198): 1072-1078. [9]Chang F T, McGhie J D, Chan F L, et al. PML bodies provide an important platform for the maintenance of telomeric chromatin integrity in embryonic stem cells[J]. Nucleic Acids Res, 2013 , 41(8): 4447-4458. [10]Karwacki-Neisius V, Goke J, Osomo R, et al. Reduced Oct4 expression directs a robust pluripotent state with distinct signaling activity and increased enhancer occupancy by Oct4 and Nanog[J]. Cell Stem Cell, 2013, 12(5): 531-545. [11]Koo B S, Lee S H, Kim J M, et al. Oct4 is a critical regulator of stemness in head and neck squamous carcinoma cells[J].？ Oncogene, 2014, doi: 10. 1038/onc. 2014. 174. [Epub ahead of print]. [12]Boumahdi S, Driessens G, Lapouge G, et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma[J]. Nature, 2014, 511(7508): 246-250. [13]金世龙, 余天雾, 黄中荣, 等. As2O3在HuH7及CD13+CD133+LCSCs增殖和分化中作用的初步观察[J]. 第三军医大学学报, 2012, 34(18): 1857-1861.
[2]
王勇,唐川,兰曦,等.沉默CD133基因对CD133+肝癌干细胞放射敏感性的影响[J].第三军医大学学报,2012,34(23):2373. Wang Yong,Tang Chuan,Lan Xi,et al.RNAi targeting CD133 enhances radiosensitivity in CD133 positive liver cancer stem cells[J].J Third Mil Med Univ,2012,34(02):2373. [2]贾茜,高建,张小丽,等.HepG2、Hep3B细胞中肿瘤干细胞相关标志分子的表达[J].第三军医大学学报,2012,34(09):852. Jia Qian,Gao Jian,Zhang Xiaoli,et al.Expression of cancer stem cell-associated markers in liver cancer cell lines HepG2 and Hep3B[J].J Third Mil Med Univ,2012,34(02):852. [3]侯妍利,唐敏,陈兴月,等.分离、鉴定CD133+人肝癌干细胞以及131I-CD133mAb对其生物学效应的影响[J].第三军医大学学报,2014,36(03):222. Hou Yanli,Tang Min,Chen Xingyue,et al.Isolation and identification of CD133-positive liver cancer stem cells and 131I-CD133mAb biological effects on the cells[J].J Third Mil Med Univ,2014,36(02):222. [4]彭维,赵湘湘,苏立,等.miR-125b对肝癌干细胞自我更新能力的调控作用[J].第三军医大学学报,2015,37(11):1070. Peng Wei,Zhao Xiangxiang,Su Li,et al.miR-125b regulates self-renewal in liver cancer stem cells[J].J Third Mil Med Univ,2015,37(02):1070.
